Published April 8, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses estrogen-progestogen (Bijuva) in oral capsules, 0.5 mg estradiol (as estradiol hemihydrate)/100 mg progesterone and 1 mg estradiol (as estradiol hemihydrate)/100 mg progesterone.
- Indication: For the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with an intact uterus.